Peter Van der Ley
Overview
Explore the profile of Peter Van der Ley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin W, Luis C, Jungbluth S, Slezak M, Verreck F, Spiegel H, et al.
Vaccines (Basel)
. 2025 Jan;
12(12.
PMID: 39772106
TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine...
2.
Van der Ley P, Schijns V
Curr Opin Immunol
. 2023 Aug;
84:102376.
PMID: 37598549
Delivery of vaccines via the mucosal route is regarded as the most effective mode of immunization to counteract infectious diseases that enter via mucosal tissues, including oral, nasal, pulmonary, intestinal,...
3.
Saha S, Pupo E, Zariri A, Van der Ley P
Microlife
. 2023 May;
3:uqac011.
PMID: 37223360
Lipopolysaccharide (LPS) is for most but not all Gram-negative bacteria an essential component of the outer leaflet of the outer membrane. LPS contributes to the integrity of the outer membrane,...
4.
Pupo E, Van der Ley P, Meiring H
Anal Chem
. 2021 Nov;
93(48):15832-15839.
PMID: 34807566
The variable modification of the outer membrane lipopolysaccharide (LPS) in Gram-negative bacteria contributes to bacterial pathogenesis through various mechanisms, including the development of antibiotic resistance and evasion of the immune...
5.
Schijns V, Majhen D, Van der Ley P, Thakur A, Summerfield A, Berisio R, et al.
Pharmaceutics
. 2021 Apr;
13(4).
PMID: 33917629
Vaccines are the most effective medical intervention due to their continual success in preventing infections and improving mortality worldwide. Early vaccines were developed empirically however, rational design of vaccines can...
6.
Arenas J, Pupo E, Phielix C, David D, Zariri A, Zamyatina A, et al.
Vaccines (Basel)
. 2020 Oct;
8(4).
PMID: 33050234
Whooping cough, or pertussis, is an acute respiratory infectious disease caused by the Gram-negative bacterium Whole-cell vaccines, which were introduced in the fifties of the previous century and proved to...
7.
Arenas J, Pupo E, de Jonge E, Perez-Ortega J, Schaarschmidt J, Van der Ley P, et al.
J Biol Chem
. 2019 Mar;
294(20):7982-7989.
PMID: 30926608
Lipopolysaccharides are anchored to the outer membrane of Gram-negative bacteria by a hydrophobic moiety known as lipid A, which potently activates the host innate immune response. Lipid A of ,...
8.
Jennings M, Van der Ley P, Wilks K, Maskell D, Poolman J, Moxon E
Mol Microbiol
. 2017 Aug;
10(2):361-369.
PMID: 28776852
The galE gene from Haemophilus influenzae was used as a hybridization probe for the galE gene of Neisseria meningitidis Group B, identifying two different homologous loci. Each of the loci...
9.
Kuipers K, Jong W, van der Gaast-de Jongh C, Houben D, van Opzeeland F, Simonetti E, et al.
Infect Immun
. 2017 Jul;
85(10).
PMID: 28717032
Serotype-specific protection against is an important limitation of the current polysaccharide-based vaccines. To prevent serotype replacement, reduce transmission, and limit the emergence of new variants, it is essential to induce...
10.
Zariri A, Pupo E, van Riet E, van Putten J, Van der Ley P
Sci Rep
. 2016 Nov;
6:36575.
PMID: 27841285
Neisseria meningitidis contains a very potent hexa-acylated LPS that is too toxic for therapeutic applications. We used systematic molecular bioengineering of meningococcal LPS through deletion of biosynthetic enzymes in combination...